The latest announcement is out from Tiziana Life Sciences ( (TLSA) ).
On May 9, 2025, Tiziana Life Sciences announced significant findings from a PET scan showing a marked reduction in microglia activation in a moderate Alzheimer’s disease patient treated with intranasal foralumab for three months. This reduction in microglia activation, a key indicator of neuroinflammation, suggests that foralumab could play a crucial role in mitigating neuroinflammation in Alzheimer’s patients. The data was presented at the 2025 AD/PD Conference and highlights the potential of foralumab as a standalone or adjunctive therapy for Alzheimer’s disease, addressing an area of significant unmet need.
More about Tiziana Life Sciences
Tiziana Life Sciences is a clinical-stage biopharmaceutical company focused on developing breakthrough therapies using innovative drug delivery technologies. The company is pioneering an intranasal approach with its lead candidate, intranasal foralumab, a fully human anti-CD3 monoclonal antibody, which has shown promising safety and efficacy in clinical studies. Tiziana aims to improve immunotherapy delivery and has patented its technology for broad applications.
Average Trading Volume: 728,545
Technical Sentiment Signal: Buy
Current Market Cap: $175M
Find detailed analytics on TLSA stock on TipRanks’ Stock Analysis page.